Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis

2009 ◽  
Vol 30 (1) ◽  
pp. 57-62 ◽  
Author(s):  
Cláudia Diniz Lopes Marques ◽  
Ângela Luzia Branco Pinto Duarte ◽  
Virginia Maria Barros de Lorena ◽  
Joelma Rodrigues Souza ◽  
Wayner Vieira Souza ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Interferon Gamma ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Gamma Assay

scholarly journals Effect of Tuberculin Skin Test on Ex-vivo Interferon-gamma Assay for Latent Tuberculosis Infection

2005 ◽  
Vol 59 (4) ◽  
pp. 406 ◽  
Author(s):  
Jung Yeon Lee ◽  
Hee Jin Choi ◽  
Sang-Nae Cho ◽  
I-Nae Park ◽  
Yeon-Mok Oh ◽  
...  
Keyword(s):  
Tuberculin Skin Test ◽  
Skin Test ◽  
Interferon Gamma ◽  
Latent Tuberculosis Infection ◽  
Ex Vivo ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Gamma Assay

scholarly journals Elevated Rates of Indeterminate Results on QuantiFERON®-TB Gold Plus in COVID-19 Patients

2021 ◽  
Author(s):  
Kileen L. Shier
Keyword(s):  
Critically Ill ◽  
Interferon Gamma ◽  
Clinical Microbiology ◽  
Latent Tuberculosis Infection ◽  
Immunosuppressive Agents ◽  
Latent Tuberculosis ◽  
Interferon Γ ◽  
Cytokine Expression ◽  
Tuberculosis Infection ◽  
Interferon Gamma Release Assays

Interferon-gamma release assays are used to screen various patient populations for latent tuberculosis infection. In this issue of the Journal of Clinical Microbiology, Ward et al. (J Clin Microbiol 59:e00811-21, 2021, https://doi.org/10.1128/JCM.00811-21 ) investigated an increased indeterminate rate in the QuantiFERON-TB Gold Plus assay among COVID-19 patients that was independent of immunosuppressive agents and lymphopenia. In their study, COVID-19 patients with indeterminate QuantiFERON-TB Gold Plus results trended toward decreased survival as well as increased serum IL-6 and IL-10 levels, though the differences were not statistically significant. They suggest that this pattern of cytokine expression supports an impairment of Th1, and specifically interferon-γ production, in critically ill COVID-19 patients, as indicated by indeterminate QuantiFERON-TB Gold Plus results. Clinicians should be aware of the increased rate of indeterminate QuantiFERON-TB Gold Plus results in critically ill COVID-19 patients.

Sign in / Sign up

Export Citation Format

Share Document